Foghorn Therapeutics (FHTX) Operating Leases (2019 - 2026)

Foghorn Therapeutics has reported Operating Leases for 8 years, with the latest figure at $40.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 55.92% year-over-year to $40.1 million; the trailing twelve-month figure through Mar 2026 stood at $40.1 million (up 55.92% YoY), and the FY2025 full-year result was $40.3 million, up 8.66% from the prior year.
• Operating Leases for Q1 2026 stood at $40.1 million, down from $40.3 million in the prior quarter.
• The five-year high for Operating Leases was $51.5 million in Q4 2022, with the low at $15.8 million in Q3 2025.
• Average Operating Leases over 5 years is $37.2 million, with a median of $38.7 million recorded in 2023.
• Year-over-year, Operating Leases sank 47.94% in 2025 and soared 55.92% in 2026.
• Tracing FHTX's Operating Leases over 5 years: stood at $51.5 million in 2022, then retreated by 29.03% to $36.6 million in 2023, then rose by 1.58% to $37.1 million in 2024, then grew by 8.66% to $40.3 million in 2025, then slipped by 0.54% to $40.1 million in 2026.
• The last three Operating Leases figures came in at $40.1 million (Q1 2026), $40.3 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.

Peer Comparison